Proteomic and histopathological characterisation of sicca subjects and primary Sjögren’s syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers by Aqrawi, Lara Adnan et al.
RESEARCH ARTICLE Open Access
Proteomic and histopathological
characterisation of sicca subjects and
primary Sjögren’s syndrome patients
reveals promising tear, saliva and
extracellular vesicle disease biomarkers
Lara A. Aqrawi1†, Hilde Kanli Galtung2*† , Eduarda M. Guerreiro2, Reidun Øvstebø3, Bernd Thiede4,
Tor Paaske Utheim2,3,5, Xiangjun Chen1,6, Øygunn Aass Utheim3,6, Øyvind Palm7, Kathrine Skarstein8,9 and
Janicke Liaaen Jensen1
Abstract
Background: Mononuclear cell infiltration of exocrine glands, production of Ro/SSA and La/SSB autoantibodies,
along with oral and ocular dryness, are characteristic features of primary Sjögren’s syndrome (pSS). Non-SS sicca
subjects, an underexplored group in relation to pSS, display similar sicca symptoms, with possible mild signs of
inflammation in their salivary glands, yet with no serological detection of autoantibody production. In this study, we
investigated inflammatory manifestations in the salivary gland tissue, tear fluid and saliva of non-SS subjects, as
compared to pSS patients and healthy individuals.
Methods: Fifteen non-SS, 10 pSS and 10 healthy subjects were included in the analyses. Histological evaluation of
salivary gland biopsies was performed. Liquid chromatography-mass spectrometry (LC-MS) was conducted on tear
fluid and stimulated whole saliva, and proteomic biomarker profiles were generated. Extracellular vesicle (EVs)
isolation and characterisation from both fluids were also combined with LC-MS. The LC-MS data were analysed for
quantitative differences between patient and control groups using Scaffold. Database for Annotation, Visualization
and Integrated Discovery (DAVID) and Functional Enrichment Analysis Tool (FunRich) were applied for functional
analyses.
Results: Histopathological evaluation of salivary gland biopsies showed implications of milder inflammation in non-
SS subjects through mononuclear cell infiltration, fibrosis and fatty replacement, as compared to pSS patients.
Although unaffected in the non-SS group, upregulation of proinflammatory pathways and proteins involved in
ubiquitination (LMO7 and HUWE1) and B cell differentiation (TPD52) were detected in tear fluid of pSS patients.
Moreover, overexpression of proteins STOM, ANXA4 and ANXA1, regulating cellular innate and adaptive
immunological pathways, were further identified in EVs from tear fluid of pSS patients. Finally, whole saliva and EVs
isolated from whole saliva of pSS patients expressed proteins vital for innate MHC class I cellular regulation (NGAL)
and T cell activation (CD44).
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Conclusions: Non-SS sicca subjects may show implications of mild inflammation in their glandular tissue, while
their protein profile was strikingly more similar to healthy controls than to pSS patients. Hence, the tear and salivary
biomarkers identified could be implemented as potential non-invasive diagnostic tools that may aid in increasing
diagnostic accuracy when evaluating non-SS subjects and pSS patients and monitoring disease progression.
Keywords: Sjögren’s syndrome, Autoimmunity, Sicca subjects, Proteomics, Biomarkers, Innate immunity, Adaptive
immunity, Tears, Saliva, Extracellular vesicles,
Background
Primary Sjögren’s syndrome (pSS) is a systemic rheumatic
autoimmune disease that is characterised by chronic in-
flammation, autoantibody production and destruction of
exocrine glands through mononuclear cell infiltration.
The primary target organs are the lacrimal and salivary
glands [1, 2], resulting in reduced secretion of tears and
saliva [3]. The main classification criteria used today for
pSS are the American-European Consensus Group
(AECG) criteria from 2002 [4, 5] and the American Col-
lege of Rheumatology (ACR) criteria from 2012 [6]. In
addition to evaluating symptoms of ocular and oral dry-
ness, assessing the secretory ability of exocrine glands,
and screening for anti-Ro and anti-La autoantibodies,
minor salivary gland biopsies are evaluated for mono-
nuclear cell infiltration, also known as focus scoring [7].
This routine histological assessment has been employed
to describe salivary gland involvement in SS [8, 9], where
a biopsy of focus score ≥ 1 (i.e., ≥ 1 foci per 4mm2) is con-
sidered positive. In some cases, subjects may display sicca
symptoms and may show some mild infiltration of mono-
nuclear cells in their exocrine glands, yet serologically no
autoantibody production is detected [10]. Hence, these
underexplored non-SS sicca subjects represent an interest-
ing study group when compared to both pSS patients and
healthy individuals, since they lack the characteristic fea-
tures for attaining the pSS diagnosis, yet possess the
symptomatic characteristics of ocular and oral dryness
nonetheless. Whether these alterations are the result of a
different disease course stands to be determined.
Interestingly, the destruction of salivary gland tissue
through the deregulated infiltration and proliferation of
lymphocytes may also lead to the formation of ectopic
germinal centre (GC)-like structures in approximately
20% of pSS patients [11–14]. It is also commonly accom-
panied by the development of both adipose (fatty) tissue
and fibrosis [15]. The presence of adipose tissue replace-
ment has also been observed in non-SS sicca subjects, yet
to a lesser degree [16, 17]. Hence, evaluating the degree of
adipose tissue replacement as part of routine salivary
gland assessment has been suggested as an additional
helpful tool when classifying pSS patients [16].
In view of currently available diagnostic tools for pSS,
there is an unmet need for the incorporation of non-
invasive, more accurate diagnostics. Studying the prote-
ome of biological fluids and screening for disease-spe-
cific biomarkers [18] through liquid chromatography-
mass spectrometry (LC-MS) [19, 20] has therefore been
in focus over the last decades. Both saliva [18, 21–27]
and tear fluid [28, 29] have previously been analysed to
identify potential biomarkers for SS. Moreover, salivary
and tear fluid samples can easily be obtained using a
simple, non-invasive, and fairly safe procedure that also
permits repetition and multiple collections. The majority
of proteomic studies of SS have chosen saliva as the
ideal biological fluid for performing LC-MS analyses,
under both stimulated and unstimulated conditions. As
a result, several common biomarkers for SS have been
identified, including highly abundant immune-system-
related molecules, secretory proteins, enzymes, and cyto-
kines [19, 26, 30]. Examples of such biomarkers include
β-2 microglobulin (B2MG), Neutrophil gelatinase-associ-
ated lipocalin (LCN2), Lymphocyte-specific protein 1
(LSP1), interleukin-4 (IL-4), IL-5, and Clusterin (CLU),
displaying molecules active in both innate and adaptive
immunity.
Various separation techniques can also be coupled with
proteomic analyses, in order to isolate cellular compo-
nents of interest when screening for disease biomarkers.
Extracellular vesicles (EVs) are an example of such cellular
components, comprising of exosomes (size < 100 nm),
microvesicles (size 100–1000 nm), and apoptotic bodies
(size 1000–5000 nm) [31]. Interestingly, EVs can be sep-
arated and purified through different approaches, in-
cluding size-exclusion chromatography [32–34]. They
are regarded as important mediators of intercellular
communication that can influence recipient cell func-
tions [35–37]. For instance, EVs can act as inducers
of pro-inflammatory signals on the innate immune
system during infections [38]. Patients with auto-
immune diseases have also displayed increased levels
of EVs associated with inflammation [39] and comple-
ment activation [40]. Consequently, various cell types
of the innate immune system are known to release
EVs, including natural killer (NK) cells [41], macro-
phages [42], monocytes and dendritic cells [43].
We have previously applied LC-MS using samples of
stimulated whole saliva and tear fluid from patients with
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pSS and healthy controls, in combination with EV isola-
tion, which resulted in the detection of potential novel
disease biomarkers [29, 44]. To date, non-SS sicca sub-
jects remain understudied within the field of proteomics.
Still, they represent an interesting analytical group, in re-
lation to pSS, that displays the common symptoms of
dry eyes and dry mouth, and may also show mild signs
of inflammation in their salivary gland tissue, yet remain
serologically autoantibody-negative. Whether these dis-
crepancies are the result of a different disease trajectory
remains to be explored. Hence, we wished to further in-
vestigate patterns of chronic inflammation in the salivary
gland tissue, tear fluid and saliva of these non-SS sicca
subjects. By applying histopathological assessment of
minor salivary gland biopsies, in combination with LC-
MS on tear fluid and saliva, coupled with EV isolation,
we aimed to gain insight into the cellular processes
propagating disease and delineate whether this underex-
plored group of non-SS subjects behaves more like pSS
patients or healthy controls on a glandular and protein
level. Accordingly, additional biomarkers may also be
identified, and in turn implemented as potential non-in-
vasive diagnostic tools that can aid in increasing diag-
nostic accuracy when evaluating non-SS sicca subjects




Fifteen non-SS sicca subjects, 10 pSS patients that ful-
filled the AECG classification criteria from 2002 [4] and
10 age- and gender-matched healthy controls partici-
pated in the current study. The subjects in the non-SS
group possessed dry eye and dry mouth symptoms, yet
did not fulfil the classification criteria for pSS due to
negative anti-SSA/SSB serology and a focus score < 1 in
their evaluated salivary gland biopsies. These biopsies
were collected at the Department of Oral Surgery and
Oral Medicine, University of Oslo (JLJ), and evaluated at
the Gade Laboratory for Pathology, University of Bergen
(KS). Following recruitment at the Department of
Rheumatology, Oslo University Hospital, the pSS pa-
tients, along with the non-SS sicca subjects and volun-
teering healthy controls, were all referred to the
Norwegian Dry Eye Clinic, Oslo, and the Dry Mouth
Clinic, Oslo. At these clinics, participants underwent a
thorough ocular and oral examination, followed by tear
fluid and stimulated saliva sample collection, as de-
scribed below. A detailed explanation of the study aim
and protocols was provided to the recruited subjects
upon enrolment. Written informed consent was also ob-
tained from the participants, and the Regional Medical
Ethical Committee of South-East Norway approved the
study (REK 2015/363). Medical records and clinical data
of the pSS patients were attained from the Department
of Rheumatology, Oslo University Hospital. The demo-
graphics of the non-SS and pSS subjects participating in
the current study are presented in Tables 1 and 2.
Histopathological evaluation of minor salivary gland
biopsies
Routine haematoxylin and eosin-stained sections from
minor salivary gland biopsies of the non-SS and pSS sub-
jects included in the study were evaluated using a light
microscope (Leica, DMLB, Leica Microsystems Wetzlar,
Germany). Both mononuclear cells in focal infiltrates
and those located interstitially, i.e., in close proximity to
the acinar or ductal epithelium, were analysed. Addition-
ally, other forms of tissue damage, including fibrosis, in
the same area were also investigated. Furthermore, these
salivary gland sections were scored blindly for the pres-
ence of fatty infiltration, as previously described [16, 17].
Depending on the degree of fat deposition either num-
bers 0, 1 or 2 was assigned for each category during the
assessment, where 0 was regarded negative to little,
while 1 was considered moderate, and 2 signified prom-
inent fatty infiltration.
Tear fluid and saliva collection
Participants underwent a thorough ocular surface exam-
ination at the Norwegian Dry Eye Clinic, and a detailed
oral examination at the Dry Mouth Clinic, where tear
fluid and stimulated whole saliva were collected, respect-
ively, as previously described [29, 45]. In brief, the tear
fluid was collected from both eyes using a Schirmer tear
test strip (HAAG-STREIT, Essex, UK) to produce a
minimum combined total of 10 mm of tear volume, that
was then transferred to 500 μl of 0.1 μm filtered phos-
phate-buffered saline (PBS) (Gibco, pH 7.4, Thermo-
Fisher Scientific, Oslo, Norway). Additionally, stimulated
whole saliva was collected on ice from all participants,
while chewing on a paraffin block (Paraffin Pellets, Ivo-
clor Vivadent, Shaen, Lichtenstein) for 5 min. Only pa-
tients producing ≥ 800 μl of stimulated whole saliva were
included in the study. All tear fluid and saliva samples
were then stored at − 80 °C.
Extraction of EVs from tear fluid and saliva
EVs were isolated from tear fluid and stimulated whole
saliva using size-exclusion chromatography, as described
previously [33]. In brief, due to the low volume of tear
fluid collected from the individual pSS patients, tear
fluid of Schirmer strips from all non-SS subjects, pSS pa-
tients and healthy controls were pooled into three
groups, respectively, concentrated to 200 μl using Ami-
con Ultra-4 columns, and then adjusted to a volume of
1 ml with 0.1 μm filtered PBS. Saliva samples from all
participants were centrifuged at 300 rpm for 10 min to
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remove debris, and then diluted 1:2 with 0.1 μm filtered
PBS. A qEV size-exclusion chromatography column
(iZON Science, Oxford, UK) was equilibrated by wash-
ing the column with 15ml of 0.1 μm filtered PBS.
Samples were then added to the equilibrated qEV size-
exclusion chromatography column, and 16 fractions,
each 500 μl in volume, were collected by continuously
adding 0.1 μm filtered PBS to the column. A new col-
umn was used for each sample. The eluted fractions 8–
10 (containing the majority of microvesicles and
exosomes present in the samples) were concentrated for
80 min at 30 °C in an Eppendorph concentrator 5301
(Eppendorph AG, Hamburg, Germany) and collected
into a joint fraction. The protein concentration was then
determined using Qubit Fluorometric Quantitation
(ThermoFisher Scientific, Oslo, Norway). A volume of
the tear fluid, the diluted stimulated whole saliva
(100 μl), the joint fractions from the pooled tear samples,
and from each saliva sample were then sent for prote-
omic analysis while preserved on dry ice.
Table 1 Clinical characteristics of non-SS subjects included in the proteomics analysis
Patient no. Age Gender Anti-SSA* Anti-SSB* Focus score** FI score*** Schirmer test**** Saliva secretion ***** Dry mouth Dry eyes
1 71 F – – < 1 1 + + + +
2 33 F – – 0 1 + NT + +
3 48 F – – 0 0 + + + +
4 65 F – – 0 2 + + + +
5 39 F – – 0 0 + + + +
6 44 F – – 0 0 – + + +
7 30 F – – 0 0 – + + +
8 56 F – – 0 1 + + + +
9 41 F – – 0 0 + + + +
10 50 F – – 0 0 + + + +
11 47 F – – 0 1 + – + +
12 64 F – – < 1 0 + + + +
13 73 F – – 0 2 + + + +
14 59 F – – < 1 0 + + + +
15 51 F – – < 1 – + + + +
F female, FI fatty infiltration, NT not tested
*Autoantibody production was assessed by ELISA
**Values are the number of focal infiltrates/4mm2 tissue area containing > 50 mononuclear cells
***The degree of fatty infiltration was assessed and the sections were scored blindly, where no or little fatty infiltration = 0, moderate = 1, and prominent = 2
****Values are in mm/5min; normal flow > 5mm/5 min. ‘+’ indicates dryness and tear secretion ≤ 5mm/5min
*****Values are in ml/15 min; normal flow > 1.5 ml/15 min. ‘+’ indicates dryness and unstimulated whole saliva secretion ≤ 1.5 ml/15 min
Table 2 Clinical characteristics of pSS patients included in the study
Patient no. Age Gender Anti-SSA* Anti-SSB* Focus score** GC FI score*** Schirmer test**** Saliva secretion ***** Dry mouth Dry eyes
1 48 F + + – – – + + + +
2 59 F + + – – – + + + +
3 52 F + + 8 + 1 + + + +
4 54 F + – 1 – 2 + + – +
5 60 F + + 3 + 1 + + – –
6 64 F + – 0 – 1 + + + +
7 55 F + – 0 – 2 + + + +
8 50 F + + – – – + – + +
9 35 F + + 3 + 0 + + – –
10 75 F + + – – – + – + +
F female, GC germinal centres, FI fatty infiltration
*Autoantibody production was assessed by ELISA
**Values are the number of focal infiltrates/4mm2 tissue area containing > 50 mononuclear cells
***The degree of fatty infiltration was assessed and the sections were scored blindly, where no or little fatty infiltration = 0, moderate = 1, and prominent = 2
****Values are in mm/5min; normal flow > 5mm/5 min. ‘+’ indicates dryness and tear secretion ≤ 5mm/5min
*****Values are in ml/15 min; normal flow > 1.5 ml/15 min. ‘+’ indicates dryness and unstimulated whole saliva secretion ≤ 1.5 ml/15 min
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Characterisation of EVs
In order to characterise the isolated EVs, nanoparticle
tracking analysis and immunoaffinity capture for detec-
tion of CD9 positive EVs were conducted on joint frac-
tions from saliva and tears as previously described [29].
In brief, the nanoparticle tracking analysis determined
the size distribution and concentration of the respective
EVs using a NanoSight NS500 instrument (Malvern In-
struments Ltd., Malvern, UK) [46]. The hydrodynamic
diameter of the particles in each sample was calculated
by the NTA 3.0 software (Malvern Instruments,
Malvern, UK). Additionally, immunoaffinity capture for
detection of CD9 positive EVs was performed using the
Exosome Human CD9 Flow Detection Kit (Dynal®, Ther-
moFisher Scientific, Oslo, Norway) and flow cytometry
with BD Accuri™ C6 Cytometer (BD Biosciences, Oslo,
Norway). Median fluorescence intensity (MFI) was re-
ported as a signal to noise (S/N) ratio to isotype control
from a total of 300 singlet events. A summary of the
measurements obtained from the nanoparticle tracking
analysis and the flow cytometry analyses in tear fluid
and saliva is presented in Table 3.
Protein profiling by LC-MS
Proteomics analysis was performed on saliva and tears
from non-SS sicca subjects, pSS patients, and healthy con-
trols before and after isolation of EVs, as previously de-
scribed [29]. In brief, samples were diluted with ice-cold
acetone, vortexed, precipitated overnight at − 20 °C, cen-
trifuged at 16000g for 20min at 4 °C (Centrifuge 5415R,
Eppendorf, Hamburg, Germany), and then re-dissolved in
50 μl of a mixture of 6M urea and 100mM ammonium
bicarbonate (pH 7.8), followed by reduction and alkylation
of cysteines. The alkylation reaction was quenched, and
the proteins were digested with 10 μg of trypsin for 16 h at
37 °C to generated peptides that were then purified using
an OMIX C18-micro SPE (Agilent, Santa Clara, CA, USA)
and dried using a Speed Vac concentrator (Concentrator
Plus, Eppendorf, Hamburg, Germany). These tryptic pep-
tides were analysed using an Ultimate 3000 RSLCnano-
UHPLC system connected to a Q Exactive mass spec-
trometer (Thermo Fisher Scientific, Bremen, Germany)
and a nano electrospray ion source.
For liquid chromatography separation, an Acclaim
PepMap 100 column (C18, 2 μm beads, 100 Å, 75 μm
inner diameter, 50 cm length) (Dionex, Sunnyvale CA,
USA) was used. A flow rate of 300 nL/min was employed
with a solvent gradient of 4–35% B in 60min. Solvent A
was 0.1% formic acid, and solvent B was 0.1% formic
acid/90% acetonitrile.
The mass spectrometer was operated in the data-
dependent mode to automatically switch between MS
and MS/MS acquisition. Survey full-scan MS spectra
(from m/z 400 to 2000) were acquired with the reso-
lution R = 70,000 at m/z 200, after accumulation to a
target of 1e6. The maximum allowed ion accumula-
tion times were 60 ms. The method used allowed se-
quential isolation of up to the ten most intense ions,
depending on signal intensity (intensity threshold
1.7e4), for fragmentation using higher-energy colli-
sional induced dissociation (HCD) at a target value of
1e5 charges, NCE 28, and a resolution R = 17,500.
Target ions already selected for MS/MS were dynam-
ically excluded for 30 s. The isolation window was m/
z = 2 without offset. For accurate mass measurements,
the lock mass option was enabled in MS mode.
Finally, data were acquired using Xcalibur v2.5.5, and
raw files were processed to generate peak lists in Mascot
generic format (*.mgf) using ProteoWizard release ver-
sion 3.0.331. Database searches were performed using
Mascot in-house version 2.4.0 to search the SwissProt
database (Human, 20,279 proteins), as before [29].
Table 3 Characterisation of EVs in saliva and tears
Mean particle size*
(nm)
Particles/mL* CD9 + EVs**
S/N ratio MFI
Tear fluid
Pool of patients with pSS (n = 9) 255 ± 40 5.0 E+08 1.04
Pool of patients with non-SS (n = 14) 204 ± 8 1.2 E+09 1.22
Pool of controls (n = 10) 215 ± 9 7.1 E+08 1.20
Saliva
Patients with pSS (n = 9) 233 ± 17 1.9 E+10 ± 0.7E+9 4.32 ± 1.19
Patients with non-SS (n = 14) 231 ± 13 1.0 E+10 ± 1.6E+9 3.98 ± 0.57
Controls (n = 10) 264 ± 6 7.9 E+9 ± 1.6E+9 3.22 ± 0.98
*Nanoparticle tracking analysis was conducted on EV joint fractions from pooled tear fluid (n = 9 pSS, n = 14 non-SS and n = 10 controls) and whole saliva (n = 9
pSS, n = 14 non-SS and n = 10 controls), to determine mean particle size of microvesicles and exosomes (nm ± SEM), in addition to concentrations of
EVs (particles/ml ± SEM)
**Detection of CD9+ EVs from joint fractions of pooled tear fluid (n = 9 pSS, n = 14 non-SS and n = 10 controls), and whole saliva (n = 9 pSS, n = 14 non-SS and n =
10 controls) was performed by immunoaffinity capture using anti-CD9 coated magnetic beads followed by flow cytometry analysis. The results were reported as
signal to noise (S/N) ratios of median fluorescence intensity (MFI)
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LC-MS data processing and statistical analysis
In order to validate MS/MS-based peptide and protein
identifications, Scaffold (version Scaffold_4.4, Proteome
Software Inc., Portland, OR) was used, as before [29].
Here, peptide identifications were accepted if they could
be established at greater than 95.0% probability by the
Scaffold Local FDR algorithm, while protein identifica-
tions were accepted if they could be established at
greater than 99.0% probability. For label-free quantifica-
tion, the entire MS2 total ion current (TIC) across all bio-
logical replicates was evaluated using t-test (p < 0.05). For
functional analysis of the proteomics data, Database for An-
notation, Visualization and Integrated Discovery (DAVID)
(v 6.7, https://david.ncifcrf.gov) and Functional Enrichment
Analysis Tool (FunRich) (http://www.funrich.org/) were ap-
plied. Tear fluid, stimulated whole saliva, and EVs (joint
fractions) were analysed individually, comparing pSS pa-
tients with the non-SS sicca subjects and the healthy con-
trols, correspondingly. DAVID was applied, using a False
Discovery Rate (FDR) with a maximum 5% cut-off, in order
to delineate specific cellular pathways involving these up-
regulated proteins in the pSS patients, while FunRich was
used to visualise the percentage of proteins involved in each
of these upregulated signalling pathways.
Results
Histopathological evaluation of minor salivary gland
biopsies shows patterns of chronic inflammation in the
target organ of non-SS sicca subjects
In order to account for the morphological patterns of
chronic inflammation in minor salivary gland biopsies of
the non-SS and pSS subjects included in the study, the
sections were evaluated for mononuclear cell infiltration,
other form of tissue damage including fibrosis, and for
the presence of fatty infiltration [16, 17]. Interestingly,
27% of the non-SS subjects showed some focal chronic
inflammation in their salivary gland tissue and had a
focus score value of < 1. Also, 67% of those pSS patients
that have had their biopsies taken had a positive focus
score, ranging from 1 to 8, and 50% of these biopsies
were also GC positive. Additionally, 83% of pSS patients
had a positive fatty infiltration score in their salivary
glands; where 17% had a fatty infiltration score of 0, 50%
had a score of 1, and 33% had a score of 2. Meanwhile,
40% of the non-SS sicca participants also showed fatty
infiltration in their biopsies (Tables 1 and 2). An illustra-
tion of such focal chronic inflammation and fibrosis de-
tected in the non-SS subjects, as compared to pSS
patients, is presented in Fig. 1.
Fig. 1 Histopathological evaluation of minor salivary gland biopsies shows implications of inflammation in the target organ of non-SS sicca
subjects. Haematoxylin and eosin staining of minor salivary gland biopsies taken from the non-SS and pSS subjects included in the study allowed
the evaluation for mononuclear cell infiltration, fibrosis, and the presence of fatty infiltration in their salivary gland tissue. a Non-SS subject with
normal salivary gland morphology. b Non-SS individual with fibrosis in the salivary gland tissue. c Non-SS participant with mild focal inflammation
in the salivary gland and a focus score < 1. d Salivary gland biopsy of a pSS patient with a focus score value of 3 and GC-like structure within the
focal infiltrate. Areas of inflammation are indicated by black arrow
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Upregulation of proinflammatory pathways and proteins
involved in ubiquitination and B cell differentiation
detected in tear fluid of pSS patients, as compared to
both non-SS sicca subjects and healthy controls
Performing LC-MS on tear fluid from 15 non-SS sicca
subjects, 10 pSS patients, and 10 healthy controls helped
identify significantly upregulated proteins with p values
< 0.05 that were distinguished using spectral counts
(Additional file 4: Table S1 and Additional file 5: Table
S2). These upregulated proteins were further analysed
using DAVID, and cellular processes for the upregulated
proteins in the pSS patients were detected. Upregulated
signalling pathways identified in the pSS patients, as
compared to non-SS sicca controls, included Wnt recep-
tor signalling (20.6%), MAP kinase cascade, ubiquitina-
tion, tumour necrosis factor (TNF)-mediated signalling,
T cell receptor signalling, Fc receptor signalling, NF-
kappa B cascade, MHC class I antigen processing and
presentation, IL-1 mediated signalling, in addition to
general innate immune responses, apoptotic processes,
and inflammatory responses, in descending order, as in-
dicated by the percent values of the upregulated proteins
involved in each cellular process (Fig. 2a). Similarly,
when comparing these pSS patients to the healthy con-
trols, the same cellular processes were observed as a re-
sult of upregulated proteins in the patients, with the
addition of MHC class II antigen processing and presen-
tation, and catabolic processes (Fig. 2b).
Since proteins found upregulated in the pSS patient
group could be the most promising candidates for po-
tential disease biomarkers, we also considered the num-
ber of spectral counts in our analyses. Accordingly, the
three most upregulated proteins in pSS patients that are
involved in immunological reactions, when compared to
both non-SS subjects and healthy controls, were LIM
domain only protein 7 (LMO7), E3 ubiquitin-protein lig-
ase HUWE1 (HUWE1) and Tumour protein D52
(TPD52), in descending order. The most upregulated
protein in tear fluid of patients with pSS, namely LMO7,
is involved in ubiquitination and cell adhesion. More-
over, HUWE1, also mediates ubiquitination, in addition
to neutrophil degranulation and cell differentiation.
Lastly, TPD52 plays a central role in regulating B cell
differentiation (Table 4, Additional file 1: Figure S1).
Overexpression of proteins regulating cellular innate and
adaptive immunological pathways detected in EVs from
tear fluid of pSS patients, utilising non-SS sicca subjects
and healthy individuals as controls
The DAVID analysis of the pooled tear sample from
15 non-SS subjects and 10 pSS patients, respectively,
revealed upregulated cellular pathways in pSS patients
involved in retina homeostasis (83.3%), metabolic pro-
cesses, regulation of NF-kappaB import, erythrocyte
homeostasis, MAP kinase cascade, removal of super-
oxide radicals, regulation of programmed cell death,
natural killer cell cytotoxicity and activation, response
to oxidative stress, as well as regulation of cell prolif-
eration and apoptotic processes, in downward order,
as determined by the percent values of the upregu-
lated proteins contributing to each cellular process
(Fig. 3a). Similarly, the most upregulated cellular pro-
cesses in the pSS patient group when compared to
the healthy controls was retina homeostasis (77.8%),
followed by other central innate and adaptive immune
responses (Fig. 3b).
When comparing non-SS participants to pSS patients,
no significant proteins were found to be significantly up-
regulated in the patients. However, proteins expressed
significantly more in the pSS patient group compared to
the healthy controls were erythrocyte band 7 integral
membrane protein (STOM), Annexin A4 (ANXA4) and
Annexin A11 (ANXA11). STOM is involved in neutro-
phil degranulation and regulation of viral genome replica-
tion, while ANXA4 affects NF-kappaB binding, apoptosis,
and interleukin-8 secretion. Finally, ANXA11 regulates
MHC class II protein complex binding and phagocytosis.
Whole saliva and EVs isolated from whole saliva revealed
proteins vital for innate MHC class I cellular regulation
and T cell activation in pSS patients
The LC-MS conducted on stimulated whole saliva from
15 non-SS sicca subjects, 10 pSS patients and 10 healthy
controls aided in the identification of significantly upreg-
ulated proteins in the patient group when compared to
non-SS sicca subjects and healthy controls, respectively
(Additional file 6: Table S3 and Additional file 7: Table
S4). Furthermore, significantly upregulated proteins for
pSS patients found in EVs of whole saliva were distin-
guished in a similar manner (Additional file 8: Table S5
and Additional file 9: Table S6). However, the DAVID
analysis performed on these highly expressed proteins
did not reveal any signalling pathways involving cellular
processes to be significantly affected in the patient
group.
Considering the number of spectral counts, the three
most overexpressed proteins in the pSS patient group
when compared to the non-SS sicca participants were
peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP1A),
CD44 antigen (CD44) and B2MG. The most upregulated
of these proteins, FKBP1A, plays a role in T cell activation
in FOXP3 expression and regulatory T cell suppression, in
addition to promoting tumour growth and progression.
Meanwhile, B2MG mediates antigen processing and pres-
entation on MHC class I, and innate immunity. When
comparing patients with pSS to healthy controls, proteins
Secreted Ly-6/uPAR-related protein 1 (SLUR1), B2MG,
and Clusterin (CLUS) were highly expressed in the patient
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group, in declining order. SLUR1 affects acetylcholine re-
ceptor activity, cell migration and proliferation, while
CLUS plays modulates NF-kappa-B activity and TNF pro-
duction (Table 5, Additional file 2: Figure S2).
Viewing the spectral counts of proteins identified in
EVs of whole saliva, the three most upregulated proteins
in patients with pSS, as related to non-SS sicca partici-
pants, included CD44, Major vault protein (MVP), and
Neutrophil gelatinase-associated lipocalin (NGAL), also
referred to as LCN2. MVP promotes IFNγ-mediated
signalling, MAP kinase activity and neutrophil degranu-
lation, while NGAL is a tumour-associated antigen in-
volved in cell adhesion and innate immunity. Comparing
the pSS patient group with healthy controls helped dis-
tinguish proteins Ficolin-1 (FCN1), CD44 and ANXA4
as upregulated in the patient group, in descending order.
The most changed of these proteins in EVs from whole
saliva, FCN1, is a pattern-recognition receptor involved
in innate immunity and complement activation (Table 6,
Additional file 3: Figure S3).
Fig. 2 Upregulation of proinflammatory pathways detected in tear fluid of pSS patients. For functional analysis of the proteomics data, DAVID (v
6.7, https://david.ncifcrf.gov) was applied using a FDR with a maximum 5% cut-off, and cellular processes for the upregulated proteins in the pSS
patients were identified. FunRich (http://www.funrich.org/) was then used to visualise the fraction of proteins involved in each of these
upregulated signalling pathways. a Upregulated signalling pathways identified in the pSS patients, as compared to non-SS sicca controls. b
Comparing pSS patients to healthy controls helped detect similar cellular processes as with the non-SS subjects, affecting both innate and
adaptive immunological processes. Percentage values indicate the amount of overexpressed proteins involved in upregulating each of the
cellular processes identified
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Discussion
Non-SS sicca subjects represent an interesting group, in
relation to pSS, since they display the common symp-
toms of dry eyes and dry mouth, and may also display
mild signs of chronic inflammation in their salivary
gland tissue. Still, they serologically are autoantibody
negative, and their evaluated salivary gland biopsies usu-
ally have a focus score value of 0 or < 1. To date, it re-
mains undetermined whether these discrepancies are a
result of an alternate disease trajectory, and these sub-
jects remain understudied within the field of proteomics.
By investigating morphological patterns of chronic in-
flammation in the salivary gland tissue of these non-SS
sicca subjects, and studying the proteome of their bio-
logical fluids through LC-MS, in combination with size-
exclusion chromatographic extraction of EVs, we aimed
to delineate the cellular pathways propagating disease.
By doing so, we may gain further insight into whether
these subjects behave more like pSS patients or healthy
controls on glandular and protein levels. Thus, add-
itional biomarkers could also be identified and imple-
mented as potential non-invasive diagnostic tools,
encompassing both lacrimal and salivary disease target
organs. Together, these findings may aid in increasing
diagnostic accuracy when evaluating non-SS subjects
and patients with pSS and monitoring disease
progression.
In order to assess the level of chronic inflammation in
minor salivary gland biopsies of the non-SS subjects in-
cluded in this study, in relation to patients with pSS, the
sections were evaluated for mononuclear cells infiltration,
tissue damage and fatty replacement [16, 17]. Interest-
ingly, 27% of these non-SS subjects showed some focal
chronic inflammation in their salivary gland tissue, which
resulted in a slightly positive focus score of < 1, and fatty
infiltration in 40% of the cases (Table 1). Meanwhile, 67%
of pSS patients had a positive focus score, where 50% of
these biopsies were also GC positive, and 83% also had a
positive fatty infiltration score (Table 2). Hence, our
histopathological evaluation of minor salivary gland biop-
sies showed clear implications of chronic inflammation in
the target organ of non-SS sicca controls, in the form of
focal inflammation, fibrosis and fatty infiltration, although
to a lesser degree than pSS patients (Fig. 1).
To delineate cellular pathways involving the upregu-
lated proteins identified with LC-MS in the tear fluid
samples from pSS patients, in relation to non-SS sicca
controls and healthy individuals, GO and Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway
overrepresentation analyses were performed using DA-
VID. Our results demonstrated pathways in the pSS pa-
tients involving inflammatory innate immune responses,
such as MHC class I antigen processing and presenta-
tion, TNF-mediated signalling and IL-1 mediated signal-
ling. Additional T cell receptor signalling of the adaptive
immune response, and apoptotic processes through
MAP kinase cascade, were also detected (Fig. 2). Inter-
estingly, similar cellular processes were observed as a re-
sult of upregulated proteins in the pSS patients, when
compared to both non-SS sicca subjects and healthy in-
dividuals. Moreover, the three most upregulated pro-
teins identified in tear fluid of pSS patients were
similar, when compared to both non-SS subjects and
healthy controls, namely LMO7, HUWE1 and TPD52
(Table 4, Additional file 1: Figure S1). Here, LMO7
and HUWE1 are both involved in the post-transla-
tional modification processes of ubiquitination [47,
48], similar to the SS autoantigen Ro52 [49], also
known as E3 ubiquitin ligase. Meanwhile, TPD52
plays a central role in adaptive immunity by regulat-
ing B cell differentiation [50]. Taken together, these
identified cellular pathways and proteins in tear fluid
of pSS patients imply the involvement of innate and
adaptive immune systems, where non-SS sicca sub-
jects showed similar behavioural tendencies as healthy
controls on a protein level.
Our proteomic analysis of EVs extracted from pooled
tear samples revealed upregulated cellular pathways in
Table 4 Highly upregulated proteins in tear fluid of pSS patients
Number Gene Related protein* Classification and function**
Non-SS vs. pSS
1 LMO7 LIM domain only protein 7 Ubiquitination, cell signalling, cell adhesion
2 HUWE1 E3 ubiquitin-protein ligase HUWE1 Mediates ubiquitination, neutrophil degranulation, cell differentiation
3 TPD52 Tumour protein D52 B cell differentiation, cell proliferation, Ca2+-signalling
Controls vs. pSS
1 LMO7 LIM domain only protein 7 Ubiquitination, cell signalling, cell adhesion
2 HUWE1 E3 ubiquitin-protein ligase HUWE1 Mediates ubiquitination, neutrophil degranulation, cell differentiation
3 TPD52 Tumour protein D52 B cell differentiation, cell proliferation, Ca2+-signalling
*The three most upregulated immunological proteins in whole saliva of pSS patients deviating in replicates, i.e. number of individuals (frequency), and spectral
counts, as identified by proteomics analysis and Scaffold (v 4.4.6, http://www.proteomesoftware.com/products/scaffold/)
**The classification and functions of the proteins presented were identified using publicly available databases, such as UniProt (http://www.uniprot.org)
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pSS patients, as compared to non-SS sicca subjects, in-
volving retina homeostasis, regulation of metabolic pro-
cesses, programmed cell death, natural killer cell
cytotoxicity and cell proliferation. Correspondingly, the
most upregulated of cellular processes in the patient
group when compared to the healthy controls was also
retina homeostasis, in addition to other adaptive and in-
nate immune responses (Fig. 3). Still, no significant pro-
teins were found to be upregulated in the patients when
compared to non-SS sicca subjects. This could be a con-
sequence of pooling the tear samples from individuals in
each of the study groups prior to EV extraction, due to
the compromised tear production in pSS and non-SS
subjects, resulting in loss of insight into variability be-
tween the samples. Nonetheless, the most upregulated
protein in pSS patients as related to healthy controls,
STOM, involves neutrophil degranulation and regulation
of viral genome replication [51], suggesting the involve-
ment of viral infection in SS pathogenesis, as previously
reported [23]. Meanwhile, ANXA4 and ANXA11 involve
innate immune responses and phagocytosis [52, 53], im-
plying interplay between innate and adaptive immunity,
Fig. 3 Overexpression of proteins regulating cellular innate and adaptive immunological pathways detected in EVs from tear fluid of pSS patients.
Following LC-MS of EVs extracted from tear fluid, DAVID analysis (v 6.7, https://david.ncifcrf.gov) was applied using a FDR with a maximum cut-off
of 5%. Cellular processes for the upregulated proteins in the pSS patients were identified, and FunRich (http://www.funrich.org/) was then used
to visualise the segment of proteins involved. a Upregulated signalling pathways distinguished in EVs isolated from tears of pSS patients, as
compared to non-SS subjects. b Comparing pSS patients to healthy controls, the most upregulated of cellular processes in the pSS patient group
was again retina homeostasis, followed by other central innate and adaptive immune responses. Percentage values represent the fraction of
overexpressed proteins contributing to the upregulation of each cellular process
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both as a consequence of disease pathogenesis and prob-
ably also as part of the healing process.
The DAVID analysis performed on highly expressed
proteins identified in whole saliva, and EVs separated
from whole saliva, did not disclose significantly affected
signalling pathways in the pSS patient group. Neverthe-
less, when considering the number of spectral counts,
we managed to identify the three most overexpressed
proteins in the whole saliva of pSS patients (Table 5,
Additional file 2: Figure S2). When compared to non-SS
sicca subjects, the two most upregulated of these pro-
teins in pSS patients, FKBP1A and CD44, play a role in
adaptive immunity through T-cell activation and prolif-
eration [54, 55], in addition to promoting tumour
growth and progression. Concurrently, B2MG is central
in innate immunity by mediating antigen processing and
presentation on MHC class I [56]. Comparing patients
with pSS to healthy controls, CD44 was again identified,
in addition to SLUR1, affecting acetylcholine receptor
activity, cell migration and proliferation, and CLUS,
playing a key role in innate immunity by modulating
NF-kappa-B activity and TNF production [57, 58].
Highly upregulated proteins identified in EVs of whole
saliva in patients with pSS, as related to non-SS sicca
participants, also included CD44, in addition to MVP,
and NGAL (LCN2) (Table 6, Additional file 3: Figure
S3). We have previously demonstrated NGAL to be up-
regulated in the proteome of patients with pSS [29]. Be-
ing a protein involved in the activation of neutrophils
[59] further strengthens the notion of a role for viral in-
fection in the pathogenesis of SS. Hence, NGAL could
be viewed as a potential biomarker for SS, whereby
screening for NGAL in whole saliva from patients with
pSS could provide additional diagnostic accuracy. Inter-
estingly, NGAL has also been reported as a possible dis-
ease biomarker in systemic lupus erythematosus (SLE)
[60]. Furthermore, CD44 could also be viewed as a po-
tential salivary biomarker for SS, as it was shown to be
highly upregulated in both whole saliva and EVs isolated
from whole saliva of pSS patients.
Conclusions
In conclusion, non-SS sicca subjects may demonstrate
chronic inflammation in their glandular tissue, in the
form of mild mononuclear cell infiltration, along with
sicca oral and ocular symptoms, yet lack the characteris-
tic feature of autoantibody production. However, study-
ing the proteome of their biological fluids through LC-
Table 5 Highly upregulated proteins in stimulated whole saliva of pSS patients
Number Gene Related protein* Classification and function**
Non-SS vs. pSS
1 FKBP1A Peptidyl-prolyl cis-trans isomerase FKBP1A T cell activation and proliferation, upregulation of NF-kappa-B signalling
2 CD44 CD44 antigen FOXP3 expression and regulatory T cell suppression, promotes tumour growth
3 B2MG Beta-2-microglobulin Antigen processing and presentation on MHC class I, innate immunity
Controls vs. pSS
1 SLUR1 Secreted Ly-6/uPAR-related protein 1 Acetylcholine receptor activity, cell migration and proliferation
2 B2MG Beta-2-microglobulin Antigen processing and presentation on MHC class I, innate immunity
3 CLUS Clusterin Innate immunity, modulates NF-kappa-B activity and TNF production
*The three most upregulated immunological proteins in whole saliva of pSS patients deviating in replicates, i.e. number of individuals (frequency), and spectral
counts, as identified by proteomics analysis and Scaffold (v 4.4.6, http://www.proteomesoftware.com/products/scaffold/)
**The classification and functions of the proteins presented were identified using publicly available databases, such as UniProt (http://www.uniprot.org)
Table 6 Highly upregulated proteins in EVs isolated from stimulated whole saliva of pSS patients
Number Gene Related protein* Classification and function**
Non-SS vs. pSS
1 CD44 CD44 antigen FOXP3 expression and regulatory T-cell suppression, promotes tumour growth
2 MVP Major vault protein IFNγ-mediated signalling, MAP kinase activity, neutrophil degranulation
3 NGAL Neutrophil gelatinase-associated lipocalin Innate immunity, tumour-associated antigen, cell adhesion
Controls vs. pSS
1 FCN1 Ficolin-1 Pattern-recognition receptor in innate immunity, complement activation
2 CD44 CD44 antigen FOXP3 expression and regulatory T-cell suppression, promotes tumour growth
3 ANXA4 Annexin A4 NF-kappaB binding, apoptosis, IL-8 secretion
*The three most upregulated immunological proteins in whole saliva of pSS patients deviating in replicates i.e. number of individuals (frequency), and spectral
counts, as identified by proteomics analysis and Scaffold (v 4.4.6, http://www.proteomesoftware.com/products/scaffold/)
**The classification and functions of the proteins presented were identified using publicly available databases, such as UniProt (http://www.uniprot.org)
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MS, in combination with size-exclusion chromato-
graphic extraction of EVs, revealed upregulated cellular
pathways propagating disease, where these non-SS sicca
subjects showed tendencies similar to healthy controls
rather than to pSS patients. Thus, this analysis confirms
that pSS patients displaying focal sialadenitis in the saliv-
ary gland with focus score ≥ 1 and/or serum autoanti-
bodies represent a distinct entity with an alternate
disease trajectory from non-SS subjects that have focus
score values of 0 or < 1 in their glandular tissue. Further-
more, the additional panels of biomarkers identified in
this study, such as LMO7, HUWE1, NGAL and CD44,
could be implemented in future potential non-invasive
diagnostics. Together, these findings may aid in increas-
ing diagnostic accuracy when evaluating non-SS subjects
and patients with pSS, and monitoring disease progres-
sion. Future follow-up studies are necessary in order to
validate these biomarkers in larger pSS cohorts, in
addition to studying the role and expression pattern of
these cellular components immunologically.
Additional files
Additional file 1: Figure S1. Upregulated protein expression of potential
disease biomarkers identified in tear fluid of pSS patients. Considering the
mean number of spectral counts for the proteins detected in the study
groups included in our LC-MS analyses, the three most upregulated
proteins in pSS patients (black) that are involved in immunological
reactions, when compared to both non-SS subjects (grey) and healthy
controls (white), were LMO7, HUWE1, and TPD52, in descending order.
Statistical significance where p < 0.01 is indicated by (*), and p < 0.001 is
highlighted by (**). (TIFF 10515 kb)
Additional file 2: Figure S2. Upregulation of potential disease
biomarkers detected in stimulated whole saliva of pSS patients. In view of
the mean number of spectral counts of the proteins identified when
performing LC-MS analyses, the three most overexpressed proteins in the
pSS patient group (black) when compared to the non-SS sicca
participants (grey) were FKBP1A, CD44, and B2MG. Meanwhile, when
comparing patients with pSS (black) to healthy controls (white), proteins
SLUR1, B2MG, and CLUS were highly expressed in the patient group, in
declining order. Statistical significance where p < 0.01 is indicated by (*),
and p < 0.001 is highlighted by (**). (TIFF 11015 kb)
Additional file 3: Figure S3. Overexpression of proteins and potential
disease biomarkers found in EVs isolated from stimulated whole saliva in
pSS patients. Viewing the mean spectral counts of proteins identified in
EVs of whole saliva, the three most upregulated proteins in patients with
pSS (black), as related to non-SS sicca participants (grey), included CD44,
MVP, and NGAL, also referred to as LCN2. Comparing the pSS patient
group (black) with healthy controls (white) helped distinguish proteins
FCN1, CD44 and ANXA4 as upregulated in the patient group, in
decreasing order. Statistical significance where p < 0.01 is indicated by (*).
(TIFF 10937 kb)
Additional file 4: Table S1. Upregulated proteins in tear fluid of non-SS
subjects vs. pSS patients. (PDF 277 kb)
Additional file 5: Table S2. Upregulated proteins in tear fluid of controls
vs. pSS patients. (PDF 262 kb)
Additional file 6: Table S3. Upregulated proteins in whole saliva of non-
SS subjects vs. pSS patients. (PDF 177 kb)
Additional file 7: Table S4. Upregulated proteins in whole saliva of
controls vs. pSS patients. (PDF 40 kb)
Additional file 8: Table S5. Upregulated proteins in EVs isolated from
whole saliva of non-SS subjects vs. pSS patients. (PDF 206 kb)
Additional file 9: Table S6. Upregulated proteins in EVs isolated from
whole saliva of controls vs. pSS patients. (PDF 211 kb)
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